Literature DB >> 12835099

Neurotoxicity due to o-quinones: neuromelanin formation and possible mechanisms for o-quinone detoxification.

F Solano1, V J Hearing, J C García-Borrón.   

Abstract

o-Quinones are easily formed by oxidation of physiologically relevant catechols. These reactions mainly occur in two specialized cells, catecholaminergic neurons and melanocytes. Both types of cells are related ontogenetically, as they arise from the neural crest during the developmental differentiation. o-Quinones are used to form melanin, a protective pigment formed by different mechanisms in melanocytes and catecholaminergic neurons. However, the reactivity of these quinones makes their presence in the cytosol dangerous for the cell survival and these compounds have been proposed as degenerative and apoptotic agents. Thus, melanin-producing cells show several potential mechanisms to protect themselves against the noxious effects of o-quinones. In melanocytes, the most effective autoprotecting mechanisms are the existence of malanosomes as a confined site for melano-synthesis and the action of tyrosinase-related protein 2 (TRP2) to drive L-dopachrome to 5,6-dihydroxyindole-2-carboxylic acid minimizing the formation of 5,6-dihydroxyindole. In catecholaminergic neurons, recent data suggest that glutathione transferase (GST M2-2 isoenzyme) and macrophage migration inhibitory factor (MIF) are very effective in preventing long-lived formation of dopaminechrome and noradrenochrome, although the detoxification reactions are different (conjugation to GSH or isomerization respectively). These mechanisms are less efficient for adrenochrome, although MIF and GST M1-1 could also catalyze similar reactions using this compound as substrate. In addition, the formation of adrenochrome is still under discussion, and adrenolutin formation could contribute to deactivate its harmful effects. The contribution of D-dopachrome tautomerase to these mechanisms is yet unknown, although in contrast to MIF, that enzyme does not recognize catecholaminechromes as substrates. Diaphorase could also be protective against quinones, since this enzyme catalyzes their bielectronic reduction back to catechols, thus preventing the formation of chrome species. This activity has been described in melanocytes and neurons, so that its contribution should be further investigated. In contrast to diaphorase, cytochrome P450 reductase should not be considered a protective enzyme, since its monoelectronic reduction of quinones leads to formation of semiquinones, that is, even more noxious than the quinones.

Entities:  

Year:  2000        PMID: 12835099     DOI: 10.1007/bf03033287

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  83 in total

Review 1.  Protein oxidation in aging, disease, and oxidative stress.

Authors:  B S Berlett; E R Stadtman
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

Review 2.  Extra-cutaneous melanin.

Authors:  A S Breathnach
Journal:  Pigment Cell Res       Date:  1988

3.  Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes.

Authors:  S Baez; J Segura-Aguilar; M Widersten; A S Johansson; B Mannervik
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

4.  The protective effect of superoxide dismutase and catalase against formation of reactive oxygen species during reduction of cyclized norepinephrine ortho-quinone by DT-diaphorase.

Authors:  Y Linderson; S Baez; J Segura-Aguilar
Journal:  Biochim Biophys Acta       Date:  1994-07-06

5.  Neuromelanin synthesis in rat and human substantia nigra.

Authors:  J M Rabey; F Hefti
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1990

Review 6.  Binding of dopaminergic drugs by the neuromelanin of the substantia nigra, synthetic melanins and melanin granules.

Authors:  M Salazar; T D Sokoloski; P N Patil
Journal:  Fed Proc       Date:  1978-08

7.  Cysteinyldopamine is not incorporated into neuromelanin.

Authors:  K Wakamatsu; S Ito; T Nagatsu
Journal:  Neurosci Lett       Date:  1991-09-30       Impact factor: 3.046

8.  Possible role of neuromelanin in the pathogenesis of Parkinson's disease.

Authors:  D M Mann; P O Yates
Journal:  Mech Ageing Dev       Date:  1983-02       Impact factor: 5.432

9.  Dopamine-induced programmed cell death in mouse thymocytes.

Authors:  D Offen; I Ziv; S Gorodin; A Barzilai; Z Malik; E Melamed
Journal:  Biochim Biophys Acta       Date:  1995-08-31

10.  Tyrosinase gene expression in human tissues.

Authors:  Z Battyani; L Xerri; J Hassoun; J J Bonerandi; J J Grob
Journal:  Pigment Cell Res       Date:  1993-12
View more
  11 in total

1.  Review of apoptosis vs. necrosis of substantia nigra pars compacta in Parkinson's disease.

Authors:  R M Kostrzewa
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

2.  Mushroom tyrosinase oxidizes tyrosine-rich sequences to allow selective protein functionalization.

Authors:  Marcus J C Long; Lizbeth Hedstrom
Journal:  Chembiochem       Date:  2012-07-17       Impact factor: 3.164

Review 3.  Neurotoxins and neurotoxic species implicated in neurodegeneration.

Authors:  Juan Segura Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

4.  Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action.

Authors:  Hajer Ouertatani-Sakouhi; Farah El-Turk; Bruno Fauvet; Min-Kyu Cho; Damla Pinar Karpinar; Didier Le Roy; Manfred Dewor; Thierry Roger; Jürgen Bernhagen; Thierry Calandra; Markus Zweckstetter; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2010-06-01       Impact factor: 5.157

Review 5.  Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.

Authors:  Masato Asanuma; Ikuko Miyazaki; Norio Ogawa
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 6.  Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.

Authors:  Thomas S Guillot; Gary W Miller
Journal:  Mol Neurobiol       Date:  2009-03-04       Impact factor: 5.590

Review 7.  MIF: mood improving/inhibiting factor?

Authors:  Joshua Bloom; Yousef Al-Abed
Journal:  J Neuroinflammation       Date:  2014-01-21       Impact factor: 8.322

8.  Iris phenotypes and pigment dispersion caused by genes influencing pigmentation.

Authors:  Michael G Anderson; Norman L Hawes; Colleen M Trantow; Bo Chang; Simon W M John
Journal:  Pigment Cell Melanoma Res       Date:  2007-06-28       Impact factor: 4.693

9.  Genetic modulation of the iris transillumination defect: a systems genetics analysis using the expanded family of BXD glaucoma strains.

Authors:  Shankar Swaminathan; Hong Lu; Robert W Williams; Lu Lu; Monica M Jablonski
Journal:  Pigment Cell Melanoma Res       Date:  2013-05-13       Impact factor: 4.693

Review 10.  Novel mechanisms and approaches in the study of neurodegeneration and neuroprotection. a review.

Authors:  Richard M Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.